CliffBio
small molecule

OMTRYG

OMEGA-3-ACID ETHYL ESTERS TYPE A

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameOMTRYG
Active ingredientOMEGA-3-ACID ETHYL ESTERS TYPE A
Strength1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2014
Marketing statusDISCN

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OMTRYG patent cliff — loss of exclusivity — | CliffBio